. 2021 Sep 27;11(9):e049481. doi: 10.1136/bmjopen-2021-049481

Table 1.

Inclusion and exclusion criteria for participating in ASTARTÉ trial

Inclusion criteria	Exclusion criteria
Adult hospitalised patients with monomicrobial bacteraemia due to Enterobacterales. The micro-organism is resistant to cefotaxime, ceftriaxone (MIC >2 mg/L) and/or ceftazidime (MIC >4 mg/L). The micro-organism is susceptible to temocillin (MIC ≤8 mg/L) and meropenem (MIC ≤2 mg/L). Duration of intravenous treatment is planned to be at least 4 days. The patient signed informed consent.	Age <18 years. Pregnancy or breast feeding. Patients under palliative care. Allergy to beta-lactam drugs. Polymicrobial bacteraemia. Meningitis. Infections typically needing >14 days of therapy (eg, endocarditis, prosthetic joint infection, vascular graft infection, empyema, chronic prostatitis). Severe neutropenia (<500 cells/µL). Septic shock at recruitment. Empirical treatment with an in vitro active drug for >96 hours after initial blood culture extraction.

Inclusion criteria

Exclusion criteria

Adult hospitalised patients with monomicrobial bacteraemia due to Enterobacterales.
The micro-organism is resistant to cefotaxime, ceftriaxone (MIC >2 mg/L) and/or ceftazidime (MIC >4 mg/L).
The micro-organism is susceptible to temocillin (MIC ≤8 mg/L) and meropenem (MIC ≤2 mg/L).
Duration of intravenous treatment is planned to be at least 4 days.
The patient signed informed consent.

Age <18 years.
Pregnancy or breast feeding.
Patients under palliative care.
Allergy to beta-lactam drugs.
Polymicrobial bacteraemia.
Meningitis.
Infections typically needing >14 days of therapy (eg, endocarditis, prosthetic joint infection, vascular graft infection, empyema, chronic prostatitis).
Severe neutropenia (<500 cells/µL).
Septic shock at recruitment.
Empirical treatment with an in vitro active drug for >96 hours after initial blood culture extraction.

MIC, minimum inhibitory concentrations.